Ibrutinib and CSP, but not other immunosuppressants, induced donor transitory-Tex-CNI after allo-HCT. (A-N) Allo-HCT was performed as in Figure 1A. (A-D) Mice were administered with vehicle or indicated reagents daily from days 0 to 14 after allo-HCT. Proportions and absolute numbers of PD-1⁺TIGIT^– in 2C-Tg (A-B) and WT (C-D) CD8⁺ T cells in the spleen on day 14 (n = 6 per group). (E-J) Mice were administered with vehicle or ibrutinib daily from days 0 to 28 after allo-HCT. Absolute numbers of PD-1⁺TIGIT⁺ cells (E) and PD-1⁺TIGIT^– cells (F), MFI of TOX (G), and absolute numbers of TOX^low cells (H), in 2C-Tg (top) and WT (bottom) CD8⁺ donor T cells in the spleen on days 14 and 28 (n = 6 per group). Proportions (I) and absolute numbers (J) of Ly6C⁺ T cells in 2C-Tg and WT CD8⁺ and WT CD4⁺ donor T cells on day 28 (n = 5 per group). (K-N) Mice were administered daily with vehicle or CSP in combination with low-dose IL-2 or alone from days 0 to 14 after allo-HCT. Proportions (K) and absolute numbers (L) of PD-1⁺TIGIT^– and proportions (M) and absolute numbers (N) of Ly6C⁺ cells in 2C-Tg donor T cells in the spleen on day 14 (n = 5 per group). (A-H) Data from 2 experiments were combined and shown as means ± SEM. (I-N) Data from one of 2 similar experiments were shown as means ± SEM. ∗P < .05; ∗∗P < .01. MFI, mean fluorescence intensity; ns, not significant.